SCHEDULE: FMR LLC Boosts Stake in CytomX Therapeutics to 9.3%
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership of 9.3% of CytomX Therapeutics Inc.'s common stock, totaling 15,396,200 shares.
Summary
- FMR LLC and Abigail P. Johnson, through various entities, beneficially own 15,396,200 shares of CytomX Therapeutics Inc. common stock.
- This represents 9.3% of the total outstanding common stock of CytomX Therapeutics Inc.
- FMR LLC, a parent holding company, and its subsidiaries, including Fidelity Management & Research Company LLC, are the primary reporting entities.
- Abigail P. Johnson, as a predominant owner and CEO of FMR LLC, is also reported as a beneficial owner.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a substantial and stable beneficial ownership by a major institutional investor, FMR LLC, and its affiliates, in CytomX Therapeutics. This suggests continued confidence in the company from a prominent financial entity.
Positives
- A significant institutional investor, FMR LLC, maintains a substantial stake, indicating continued confidence in CytomX Therapeutics.
- The ownership is held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.
Risks
- No specific risks related to CytomX Therapeutics' operations or financial health are disclosed in this ownership filing.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding CytomX Therapeutics' future performance or strategy.
Management Comments
- The filing includes a certification from FMR LLC and Abigail P. Johnson that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Industry Context
The disclosure of a significant stake by a major asset manager like FMR LLC in a biotechnology company like CytomX Therapeutics can signal institutional interest in the sector or the specific company's pipeline and strategic direction. Such filings are common for institutional investors managing large portfolios.
Comparison to Industry Standards
- This filing does not provide information for direct comparison to industry standards or specific comparable companies, projects, and results. It is a disclosure of ownership.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Entity Internal Control Structure Disclosure | The filing details that members of the Johnson family, including Abigail P. Johnson, form a controlling group with respect to FMR LLC due to their ownership of Series B voting common shares and a shareholders' voting agreement. | NA | This clarifies the internal control structure of FMR LLC, the parent holding company reporting the beneficial ownership. While it describes FMR LLC's governance, it does not directly indicate changes in CytomX Therapeutics' bylaws, committees, or policies. The filing explicitly states the shares are not held for the purpose of changing or influencing control of CytomX. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC may be viewed positively, potentially signaling institutional confidence and stability in the shareholder base.
- Management: Awareness of a large, stable institutional holder may influence management's long-term strategic planning, though the filing states the stake is not for influencing control.
Next Steps
- No specific future actions, events, or milestones for CytomX Therapeutics are mentioned in this ownership filing.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 22025-09-30 | Date of event which requires filing of this statement (reporting period end for ownership calculation). |
| 2025-11-04 | Date of filing and signature for FMR LLC and Abigail P. Johnson. |
Recommendation
holdThis is a routine Schedule 13G filing disclosing a significant beneficial ownership stake by FMR LLC. While a large institutional holding can be seen as a positive signal of confidence, the filing itself does not provide new operational or financial information about CytomX Therapeutics that would warrant a change in investment recommendation. Investors should continue to monitor the company's fundamental performance and pipeline developments.
Keywords
CytomX Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.